Title of Invention

COMPOSITION FOR REDUCING BLOOD LIPIDS

Abstract A composition for reducing the blood lipids is disclosed. The composition includes the lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present invention is selected from a group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, chromium nicotinate, inorganic salts of trivalent chromium, organic salts of trivalent chromium, and combinations thereof.
Full Text BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a composition and method for
reducing the blood lipids and, more particularly, to a trivalent chromium
dairy product that can reduce the blood lipids of an acceptor and the
manufacturing method thereof.
2. Description of the Related Art
Owing to the development in economics, the change in lifestyle, and
the abundance of foods, obesity is gradually found in all age groups of
modern humans, from the children, the youth, to the aged people. The
population of obese people keeps increasing and, accordingly, there are
more and more people suffered from the derivative sickness of obesity,
such as hypertension, heart disease, and hyperlipidemia. Therefore, it is
really an important subject for the modern humans to study how to reduce
the level of blood lipids.
Normally, the trivalent chromium absorbed from foods can be
transferred into glucose tolerance factor (GTF) and then distributed in the
tissues of human bodies. GTF in the tissues assistants blood lipids and
hydrocarbons in undergoing normal metabolism through the synergistic
effect with the insulin.
It is revealed from the research that the concentration of serum
chromium decrease as one gets older. From the clinical researches in
1997, Davies verified that the concentration of serum chromium decreases
from 0.5 ng/ml at one's childhood to 0.3 ng/ml at the age of 70 years old.
Obesity is a cause that drains chromium from a human body. Moreover,
the deficiency of chromium will lead to problems in metabolism of blood
lipids, which subsequently causes hyperlipidemia and other clinical
symptoms.
Chromium may be assimilated in the forms of inorganic salt or
organic salt from the daily food. However, the assimilation rate of
inorganic chromium for human body is very low, and only ranges from
0.4% to 3%. The root cause lies in that the inorganic chromium tends to
undergo olation reaction in the digestive tract. The olation reaction may
produce bulky complex compounds that hinder the intestine tract from
assimilating.
The adequate organic chromium includes chromium picolinate,
chromium nicotinate, chromium GTF (Glucose Tolerance Factor), and
chromium yeast extract.
The supplement of organic chromium helps to remedy the
hyperlipidemia caused by the shortage of chromium. For the general adults,
chromium combined with other kinds of vitamin and mineral substance
may be deemed as a supplement of personal nutriment.
U.S. Patent No. 4,923,855 disclosed a synthetic GTF chromium
material and process therefore, in which the trivalent chromium is
combined with nicotinic acid to obtain a novel chromium product having
glucose tolerance factor. In 2002, Cefalu et al. announced that chromium
picolinate could reduce the blood lipids of a obesity mouse.
SUMMARY OF THE INVENTION
The present invention provides a composition for reducing blood
lipids. More particularly, the present invention provides a composition of
trivalent chromium compound and lactoferrin that can reduce the blood
lipids. The present invention also provides a method for reducing the
blood lipids of an acceptor. The method administrates an effective
amount of a composition that reduces blood lipids to the acceptor. The
composition is composed of trivalent chromium compound and lactoferrin.
The composition for reducing blood lipids of the present invention
mainly includes (a) a lactoferrin and (b) a trivalent chromium compound.
The lactoferrin of the present invention is not restricted, and can
come from cowmilk ferritin, goat milk ferritin, unpurifted cowmilk, and
unpurified goat milk. Because lactoferrin mainly exists in the whey of the
milk, the lactoferrin of the present invention can also be replaced with
whey protein products or milk products.
The trivalent chromium compound of the present invention is not
restricted, too. Preferably, it can be selected from a group consisting of
chromium (III) chloride hexahydrate, chromium (III) chloride, chromium
(III) acetate, chromium (III) sulfate, chromium picolinate, chromium
nicotinate, inorganic salts of trivalent chromium, organic salts of trivalent
chromium, and combinations thereof.
The inorganic salt of trivalent chromium includes, for example,
chromium (III) chloride and chromium (III) sulfate.
The organic salt of trivalent chromium includes, for example,
chromium (III) acetate, chromium picolinate, chromium nicotinate, amino
acid chelated chromium, chromium yeast extract, and chromium yeast.
More preferably, the trivalent chromium compound is chromium (III)
chloride hexahydrate, chromium (III) chloride, chromium (III) acetate,
chromium (III) sulfate, chromium picolinate, or chromium nicotinate.
Generally speaking, the molar ratio of lactoferrin to the trivalent
chromium compound of the present invention is not particularly restricted.
Preferably, the molar ratio of lactoferrin to the trivalent chromium
compound ranges from 1:200 to 10:1. More preferably, the molar ratio of
lactoferrin to the trivalent chromium compound ranges from 1:20 to 1:1.
The composition of the present invention can serve as an additive of
a dairy product. The dairy product can be the fresh milk of mammals,
long-lived milk, concentrated milk, cheese, or milk powder.
The composition containing trivalent chromium lactoferrin of the
present invention can be assimilated and utilized effectively by the human
body. Taking the dairy product having the composition of the present
invention not only can replenish the organic chromium efficiently, but also
can control the level of blood lipids of a patient suffered from
hyperlipidemia.
The composition containing trivalent chromium lactoferrin of the
present invention is formed by mixing the trivalent chromium compound
with the lactoferrin, and can enhance the normal metabolism of fat,
carbohydrates, and protein. The lactoferrin is a glycoprotein that is
capable of combining with metal ions. Each lactoferrin molecule can be
combined with two trivalent chromium ions.
The composition of the present invention can be used to form a
medicine. Also, it can be added into a dairy product, and thereby to form
a dairy product containing trivalent chromium compound and lactoferrin,
i.e., to form a food or nutriment.
The composition of the present invention can be taken by a patient
suffered from hyperlipidemia because the composition can supplement the
trivalent chromium effectively and enhance the normal metabolism of fat,
carbohydrates, and protein. In addition, the level of blood lipids can be
reduced to comfort the sufferers of hyperlipidemia.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The composition of the present invention can be formed by mixing
the powder of lactoferrin with the powder of trivalent chromium compound.
Moreover, water can also be added into the mixture of lactoferrin and the
trivalent chromium compound to form a mixed solution. The mixed
solution can be heated properly so that the mixing can be done adequately.
The heating temperature ranges around 37°C to 95°C, and preferably
ranges from 50°C to 80°C. The well-mixed solution is then spray-dried
to form the composition containing trivalent chromium lactoferrin of the
present invention.
The raw material of trivalent chromium compound used in the
present invention can be the form of inorganic slat or organic slat, such as
chromium (III) chloride hexahydrate, chromium (III) chloride, chromium
(III) acetate, chromium (III) sulfate, chromium picolinate, and chromium
nicotinate.
Lactoferrin could come from the solution or dry powder of
lactoferrin. Because lactoferrin mainly exists in the whey of the milk, the
present invention can also use an unpurified whey protein product or a
dairy product to replace lactoferrin.
The following detailed description are given by way of example and
not intended to limit the invention solely to the embodiments described
herein.
Example 1
Mix 5 g of lactoferrin powder with 0.5 g of chromium (III) chloride
hexahydrate to form the composition containing trivalent chromium
lactoferrin of the present invention.
Example 2
Mix 5 g of lactoferrin powder and 0.5 g of chromium (III) chloride
hexahydrate with 1 liter of water to form a solution. The solution is
well-mixed and then spray-dried to form the composition containing
trivalent chromium lactoferrin of the present invention.
Example 3
Mix 5 g of lactoferrin powder and 0.5 g of chromium (III)
chloride hexahydrate with 1 liter of water to form a solution. The solution
is well-mixed, spray-dried, and then mixed with 10 kg of milk powder to
form the dairy product containing trivalent chromium lactoferrin.
Example 4
Mix 100 g of whey protein and 0.5 g of chromium (III) chloride
hexahydrate with 3 liter of water to form a solution. The solution is
well-mixed and then spray-dried to form the composition containing
trivalent chromium lactoferrin of the present invention.
Example 5
The procedure of Example 4 is repeated first, and then the product is
mixed with 10 kg of milk powder to form the dairy product containing
trivalent chromium lactoferrin.
Example 6
The procedure of Example 4 is repeated, except that the mixed
solution id added into 90 kg of fresh milk to form the dairy product
containing trivalent chromium lactoferrin.
Example 7
Mix 5 g of lactoferrin powder with 0.3 g of chromium (III) chloride
to form the composition containing trivalent chromium lactoferrin of the
present invention.
Example 8
Mix 6 g of lactoferrin powder with 0.5 g of chromium acetate to
form the composition containing trivalent chromium lactoferrin of the
present invention.
Example 9
Mix 5 g of lactoferrin powder and 0.35 g of chromium sulfate with 1
liter of water to form a solution. The solution is well-mixed and then
spray-dried to form the composition containing trivalent chromium
lactoferrin of the present invention.
Example 10
Mix 5 g of lactoferrin powder and 0.8 g of chromium picolinate with
1 liter of water to form a solution. The solution is heated and mixed, and
then spray-dried to form the composition containing trivalent chromium
lactoferrin of the present invention.
Example 11
Mix 5 g of lactoferrin powder and 0.8 g of chromium nicotinate with
1 liter of water to form a solution. The solution is heated and mixed, and
then spray-dried to form the composition containing trivalent chromium
lactoferrin of the present invention.
Test Example 1
The dairy product obtained from Example 5 is added into the feed of
mice (Modified LabDiet w/35.5% Lard, PMI® Richmond, Indiana, USA).
The experimental group includes three kinds of dairy products, each of
which respectively has 200 ppb, 400 ppb, and 800 ppb of trivalent
chromium. The control group has no trivalent-chromium dairy product.
The experiment is carried out on male KK/HIJ mice with 10 weeks old.
The concentration (mg/dl) of triglyceride in blood is measured before the
experiment starts and at four weeks after the experiment starts. The result
is listed in Table 1. The concentration of triglyceride in blood of mice fed
with dairy product containing 800 ppb of trivalent chromium is obviously
lower than that of mice fed without trivalent-chromium dairy product
(P experimental-group mice fed with dairy product containing 200 ppb and
400 ppb of trivalent chromium respectively are also lower than that of
control group mice fed without trivalent-chromium dairy product.
Table 1. The variation of concentrations (mg/dl) of triglyceride in
bloods of male KK/HIJ mice fed with dairy products containing different
kinds of concentration of trivalent chromium.
The composition containing trivalent chromium lactoferrins of the
present invention can be taken by a patient suffered from hyperlipidemia
because it can regulate the level of blood lipid thereof effectively. From
Table 1, it is proven that the level of blood lipid is lowered effectively after
the dairy product containing the composition of the present invention is
taken.
Although the present invention has been explained in relation to its
preferred embodiments, it is to be understood that many other possible
modifications and variations can be made without departing from the scope
of the invention as hereinafter claimed.
WE CLAIM;
1. A composition for reducing the blood lipids, comprising:
a lactoferrin; and
a trivalent chromium compound;
wherein the trivalent chromium compound is selected from the group consisting of
chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium
(III) sulfate, chromium picolinate, chromium nicotinate, inorganic salts of trivalent chromium,
organic salts of trivalent chromium, and combinations thereof, and the molar ratio of the lactoferrin
to the trivalent chromium compound ranges from 1:200 to 10:1.
2. The composition as claimed in claim 1, wherein the molar ratio of the lactoferrin to
the trivalent chromium compound ranges from 1:20 to 1:1.
3. The composition as claimed in claim 1, wherein the lactoferrin comes from the
unpurified milk or the whey protein.
4. The composition as claimed in claim 1, wherein the lactoferrin comes from the
group consisting of cowmilk ferritin, goat milk ferritin, unpurified cowmilk, unpurified goat milk,
and combinations thereof.
5. The composition as claimed in claim 1, wherein the trivalent chromium compound
is selected from the group consisting of chromium (III) chloride hexahydrate, chromium (III)
chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, chromium
nicotinate, and combinations thereof.
6. The composition as claimed in claim 1, wherein the composition serves as an
additive of a dairy product, which is selected from a group consisting of fresh milk of mammals,
long-lived milk, concentrated milk, cheese, and milk powder.
A composition for reducing the blood lipids is disclosed. The composition includes the
lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present
invention is selected from a group consisting of chromium (III) chloride hexahydrate, chromium
(III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, chromium
nicotinate, inorganic salts of trivalent chromium, organic salts of trivalent chromium, and
combinations thereof.

Documents:

614-KOL-2005-(13-01-2012)-FORM-27.pdf

614-KOL-2005-CORRESPONDENCE-1.1.pdf

614-KOL-2005-CORRESPONDENCE.pdf

614-KOL-2005-FORM 27-1.1.pdf

614-KOL-2005-FORM 27.pdf

614-kol-2005-granted-abstract.pdf

614-kol-2005-granted-assignment.pdf

614-kol-2005-granted-claims.pdf

614-kol-2005-granted-correspondence.pdf

614-kol-2005-granted-description (complete).pdf

614-kol-2005-granted-examination report.pdf

614-kol-2005-granted-form 1.pdf

614-kol-2005-granted-form 18.pdf

614-kol-2005-granted-form 3.pdf

614-kol-2005-granted-form 5.pdf

614-kol-2005-granted-pa.pdf

614-kol-2005-granted-priority document.pdf

614-kol-2005-granted-reply to examination report.pdf

614-kol-2005-granted-specification.pdf

614-kol-2005-granted-translated copy of priority document.pdf


Patent Number 223062
Indian Patent Application Number 614/KOL/2005
PG Journal Number 36/2008
Publication Date 05-Sep-2008
Grant Date 03-Sep-2008
Date of Filing 13-Jul-2005
Name of Patentee MAXLUCK BIOTECHNOLOGY CORP.
Applicant Address 10F.,NO. 75-1, SONGJIANJ RD, JHONGSHAN DISTRICT, TAIPEI CITY 104, TAIWAN
Inventors:
# Inventor's Name Inventor's Address
1 MAO FRANK CHIAHUNG 12F-5, NO. 108, SEC.2, HANKOU RD., SITUN DISTRICT,TAICHUNG CITY 407
2 HSIAO FAN-CHIN NO. 89-1, WUCYUAN W. 5TH ST., WEST DISTRICT, TAICHUNG CITY 403
3 CHIANG YI-CHUNG 6F.,NO.2 LANE 207, SEC.7, JHONGSHAN N. RD, SHIHLIN DISTRICT,TAIPEI CITY 111
PCT International Classification Number A61 K31
PCT International Application Number N/A
PCT International Filing date
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 093123462 2004-08-05 Chinese Taipei